Activities of Dalbavancin In Vitro and in a Rabbit Model of Experimental Endocarditis Due to Staphylococcus aureus with or without Reduced Susceptibility to Vancomycin and Teicoplanin
Open Access
- 1 March 2004
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (3) , 1061-1064
- https://doi.org/10.1128/aac.48.3.1061-1064.2004
Abstract
For the treatment of rabbit endocarditis, dalbavancin given once daily (10 mg/kg of body weight for 4 days) or as a single 40-mg/kg dose was active against Staphylococcus aureus with or without reduced susceptibility to glycopeptides, as expected from its good in vitro activity, even in broth supplemented with 90% serum and given its prolonged elimination half-life.Keywords
This publication has 8 references indexed in Scilit:
- Influence of Reduced Susceptibility to Glycopeptides on Activities of Vancomycin and Teicoplanin against Staphylococcus aureus in Experimental EndocarditisAntimicrobial Agents and Chemotherapy, 2003
- In VitroEvaluation of BI 397, a Novel Glycopeptide Antimicrobial AgentJournal of Chemotherapy, 2001
- In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibioticJournal of Antimicrobial Chemotherapy, 1999
- Activity and Diffusion of LY333328 in Experimental Endocarditis Due to Vancomycin-Resistant Enterococcus faecalisAntimicrobial Agents and Chemotherapy, 1999
- First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospitalThe Lancet, 1998
- Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.1997
- Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibilityJournal of Antimicrobial Chemotherapy, 1997
- Method of reliable determination of minimal lethal antibiotic concentrationsAntimicrobial Agents and Chemotherapy, 1980